BioMarin Pharmaceutical Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | $2.77B | $348.2M |
| Jun 2017 | — | $2.80B | $354.9M |
| Sep 2017 | — | $2.81B | $431.4M |
| Dec 2017 | — | $2.81B | $598.0M |
| Mar 2018 | — | $2.81B | $474.0M |
| Jun 2018 | — | $2.89B | $427.4M |
| Sep 2018 | — | $2.91B | $882.2M |
| Dec 2018 | — | $2.97B | $494.0M |
| Mar 2019 | — | $2.94B | $364.4M |
| Jun 2019 | — | $2.96B | $307.6M |
| Sep 2019 | — | $3.07B | $423.2M |
| Dec 2019 | — | $3.12B | $437.4M |
| Mar 2020 | — | $3.24B | $476.6M |
| Jun 2020 | — | $3.24B | $818.9M |
| Sep 2020 | — | $4.05B | $1.02B |
| Dec 2020 | — | $4.10B | $649.2M |
| Mar 2021 | — | $4.16B | $667.3M |
| Jun 2021 | — | $4.24B | $641.5M |
| Sep 2021 | — | $4.26B | $617.1M |
| Dec 2021 | — | $4.27B | $587.3M |
| Mar 2022 | — | $4.39B | $605.4M |
| Jun 2022 | — | $4.50B | $619.8M |
| Sep 2022 | — | $4.57B | $761.5M |
| Dec 2022 | — | $4.60B | $724.5M |
| Mar 2023 | — | $4.66B | $580.1M |
| Jun 2023 | — | $4.78B | $694.4M |
| Sep 2023 | — | $4.90B | $785.4M |
| Dec 2023 | — | $4.95B | $755.1M |
| Mar 2024 | — | $5.07B | $747.0M |
| Jun 2024 | — | $5.29B | $972.2M |
| Sep 2024 | — | $5.41B | $675.4M |
| Dec 2024 | — | $5.66B | $942.8M |
| Mar 2025 | — | $5.79B | $1.05B |
| Jun 2025 | — | $6.03B | $1.21B |
| Sep 2025 | — | $6.06B | $1.25B |
| Dec 2025 | $597.2M | $6.09B | $1.31B |
| Mar 2026 | $1.43B | $6.21B | $2.22B |
| Jun 2026 | $3.53B | $6.32B | $874.0M |